Trial Details
RECRUITINGBasic Information
| Clinical ID | c682 |
|---|---|
| Identifier | NCT06226883 |
| Trial Title | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Inflammatory Bowel Diseases|Crohn's Disease |
| Interventions | DRUG: Placebo|DRUG: MORF-057 |
Participant Information
| Sponsor | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) |
|---|---|
| City | Lancaster |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2024-07-18 |
|---|---|
| Primary Completion Date | 2028-09 |
| Completion Date | 2030-06 |